Overview

Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Open label study of sorafenib
Phase:
Phase 2
Details
Lead Sponsor:
Swedish Medical Center
Collaborators:
Amgen
Bayer
Onyx Pharmaceuticals
Treatments:
Sorafenib